Doravirine, Rifapentine and Isoniazid Interaction

Exclusion Criteria

• •1. History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, dermatologic, psychiatric abnormalities or neurological (including stroke and chronic seizure) diseases.
• •2. \>500 mL blood or plasma donation in the 6 weeks prior to study start
• •3. Known anaphylactic or severe systemic reactions to any components of doravirine, rifapentine, isoniazid or pyridoxine.
• •4. Positive HIV, Hepatitis B or Hepatitis C virus. Evidence of prior Hepatitis B infection and immunity is not exclusionary.
• •5. Latent or active tuberculosis infection. Documented prior fully treated latent tuberculosis is not exclusionary.
• •6. Females who are postpartum \< 12 months.
• •7. Current drug or alcohol abuse.
• •8. Received study drug in another study within 4 weeks or within 5 half-lives, which ever occurring first, before first anticipated dose of study drug in this study.
• •9. Unable to refrain from use of over-the-counter, prescription (unless determined appropriate by the investigator), herbal or natural products, vitamins or supplements, or grapefruit juice/grapefruit products.
• •10. Any clinical significant findings on lab, ECG or physical exam at screening.